Comparision of Efficacy of Rosuvastatin and Simvastatin for Ischemic Stroke

OBJECTIVE: To compare clinical efficacy of rosuvastatin and simvastatin on ischemic stroke. METHODS: 150 hospitalized ischemic stroke patients were selected from our hospital during Sep. 2009-Sep. 2010. 76 patients in rosuvastatin group were given oral dose of rosuvastatin 10 mg, qd; 74 patients in simvastatin group were given oral dose of simvastatin 20 mg, qd. The changes of TC, TG, LDL-C, HDL-C and hs-CRP in fasting venous blood were compared before and after 3 months treatment. RESULTS: Rosuvastatin group and simvastatin group had no significant difference in lipid level and hs-CRP before treatment (all P0.05); TC, TG, LDL-C and hs-CRP were significantly lowered after treatment, HDL-C level was significantly increased after treatment, and rosuvastatin group had greater changes (all P0.05). The ischemic stroke recurrence rates of rosuvastatin group and simvastatin group were 7.89% (6/76) and 18.92% (14/74), respectively. That of rosuvastatin group was significantly lower than that of simvastatin group (P=0.047). The adverse drug reactions of 2 groups were mild relatively, there was no statistical significance (P0.05). CONCLUSIONS: Both of rosuvastatin and simvastatin have good lipid-lowering and anti-inflammatory effects on ischemic stroke patients, and the incidence of adverse drug reactions are similar between 2 groups. However, rosuvastatin is more effective with lower recurrence rate.